Page 112 - Read Online

Orekhov et al. Vessel Plus 2019;3:10 I http://dx.doi.org/10.20517/2574-1209.2019.04 Page 17 of
20
2010;11:889-96.
73. Bode JG, Ehlting C, Häussinger D. The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell
Signal 2012;24:1185-94.
74. Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front Immunol 2014;5:58.
75. Qin BY, Liu C, Srinath H, Lam SS, Correia JJ, et al. Crystal structure of IRF-3 in complex with CBP. Structure 2005;13:1269-77.
76. Panne D, McWhirter SM, Maniatis T, Harrison SC. Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent
switch. J Biol Chem 2007;282:22816-22.
77. Bibeau-Poirier A, Gravel SP, Clément JF, Rolland S, Rodier G, et al. Involvement of the IkappaB kinase (IKK)-related kinases tank-
binding kinase 1/IKKi and cullin-based ubiquitin ligases in IFN regulatory factor-3 degradation. J Immunol 2006;177:5059-67.
78. Zhang M, Tian Y, Wang RP, Gao D, Zhang Y, et al. Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated
degradation of IRF3. Cell Res 2008;18:1096-104.
79. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, et al. A distinct and unique transcriptional program expressed by tumor-associated
macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006;107:2112-22.
80. Tarassishin L, Suh HS, Lee SC. Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt
pathway. J Neuroinflammation 2011;8:187.
81. Lin R, Hiscott J. A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol Cell Biochem
1999;191:169-80.
82. Yanai H, Negishi H, Taniguchi T. The IRF family of transcription factors: Inception, impact and implications in oncogenesis.
Oncoimmunology 2012;1:1376-86.
83. Brass AL, Kehrli E, Eisenbeis CF, Storb U, Singh H. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for
autoinhibition and ternary complex formation with the Ets factor PU.1. Genes Dev 1996;10:2335-47.
84. Brass AL, Zhu AQ, Singh H. Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused
dimers. EMBO J 1999;18:977-91.
85. Marecki S, Fenton MJ. PU.1/Interferon Regulatory Factor interactions: mechanisms of transcriptional regulation. Cell Biochem Biophys
2000;33:127-48.
86. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host
responses against helminth infection. Nat Immunol 2010;11:936-44.
87. El Chartouni C, Schwarzfischer L, Rehli M. Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of
alternative macrophage priming. Immunobiology 2010;215:821-5.
88. Ahyi AN, Chang HC, Dent AL, Nutt SL, Kaplan MH. IFN regulatory factor 4 regulates the expression of a subset of Th2 cytokines. J
Immunol 2009;183:1598-606.
89. Honma K, Udono H, Kohno T, Yamamoto K, Ogawa A, et al. Interferon regulatory factor 4 negatively regulates the production of pro-
inflammatory cytokines by macrophages in response to LPS. Proc Natl Acad Sci USA 2005;102:16001-6.
90. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent
regulation of AP-1 activity. Mol Cell Biol 2004;24:7806-19.
91. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein.
J Biol Chem 1989;264:10867-71.
92. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 1999;274:27339-42.
93. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C,et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in
Tlr4 gene. Science 1998;282:2085-8.
94. Huang W, Ghisletti S, Perissi V, Rosenfeld MG, Glass CK. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR
derepression checkpoint. Mol Cell 2009;35:48-57.
95. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, et al. Tolerance and M2 (alternative) macrophage polarization are related processes
orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci USA 2009;106:14978-83.
96. Ziegler-Heitbrock L. The p50-homodimer mechanism in tolerance to LPS. J Endotoxin Res 2001;7:219-22.
97. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different
DNA binding affinities. Cell 1998;55:917-24.
98. Dérijard B, Hibi M, Wu IH, Barrett T, Su B, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and
phosphorylates the c-Jun activation domain. Cell 1994;76:1025-37.
99. Sluss HK, Barrett T, Dérijard B, Davis RJ. Signal transduction by tumor necrosis factor mediated by JNK protein kinases. Mol Cell Biol
1994;14:8376-84.
100. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association
and dissociation. Genes Dev 1995;9:2723-35.
101. Ghisletti S, Huang W, Jepsen K, Benner C, Hardiman G, et al. Cooperative NCoR/SMRT interactions establish a corepressor-based
strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev 2009;23:681-93.
102. Jennewein C, Kuhn AM, Schmidt MV, Meilladec-Jullig V, von Knethen A, et al. Sumoylation of peroxisome proliferator-activated
receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating
transrepression of pro-inflammatory cytokines. J Immunol 2008;181:5646-52.
103. Wiesner P, Choi SH, Almazan F, Kim J, Miller YI. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein